Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Healthy Community Project

Research Partnership launches new patient Living with Diabetes (LATAM) 2018 report

Living with Diabetes is a study conducted amongst approximately 200 Type 2 (T2D) diabetes patients in Brazil and Mexico. The report will consist of quantitative 30-minute online and qualitative telephone...

Research Partnership

- PMLiVE

Sanofi’s rare blood disorder drug Cablivi set for European approval

Rare disease drug among notable CHMP recommendations

- PMLiVE

Mylan sees the UK paving the way for an insulin game changer

As biosimilars surge into the insulin market, governments  are urged to seize ‘the opportunity of the century’

- PMLiVE

Novo’s diabetes pill defeats Merck’s Januvia in trial

Oral semaglutide also outshines its best-selling diabetes injectable Victoza

- PMLiVE

Commentary: Roseanne’s racist tweet and Sanofi’s swift and surprising riposte

Alexander Davies considers the remarkable story of how one company broke with pharma convention to speak out on social media

Sanofi reception

Sanofi poaches Peugeot’s finance head

Jean-Baptiste Chasseloup de Chatillon joins the French drugmaker as chief financial officer

- PMLiVE

Evotec says Sanofi deal makes it anti-infectives powerhouse

Aims to inject biotech nimbleness into anti-infectives portfolio

- PMLiVE

Daily Brief: Italy in turmoil, Pharma attacks Europe’s generics move and more

A rapid round up of news from pharma, biotech and healthcare

- PMLiVE

FDA starts review of Sanofi’s oral type 1 diabetes drug

The US regulator has started its review of Sanofi and Lexicon Pharma’s sotagliflozin for type 1 diabetes, which the firms say could have blockbuster potential.Sotagliflozin – which has the proposed...

- PMLiVE

Daily Brief: Immunotherapy combos dominate ASCO, Pharma’s Brexit warning, Big data and prostate cancer

News from the frontline of pharma, biotech and healthcare

- PMLiVE

Regeneron’s Dupixent and Praluent falls short

But CEO Len Schleifer says there’s time to fix that

- PMLiVE

Novo Nordisk fends off Lilly’s GLP-1 challenge in Q1

Insulin specialist bounces back with encouraging signs from Ozempic launch

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links